CompletedPhase 1NCT01407198
Nilotinib With Radiation for High Risk Chordoma
Studying Chordoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Edwin Choy, MD, PhDMassachusetts General Hospital
- Intervention
- Nilotinib(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2025
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01407198 on ClinicalTrials.govOther trials for Chordoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06957327A Study of ERAS-601 in People With ChordomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT06787664A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic ChordomaSichuan Baili Pharmaceutical Co., Ltd.
- RECRUITINGPHASE2NCT06794645Pembrolizumab and Pemetrexed for Progressive ChordomaSaint John's Cancer Institute
- RECRUITINGNCT06463262Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral ChordomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNANCT06029218Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton TherapyCentre Antoine Lacassagne
- ACTIVE NOT RECRUITINGPHASE2NCT05041127Cetuximab for the Treatment of Advanced Unresectable or Metastatic ChordomaM.D. Anderson Cancer Center
- RECRUITINGNCT05888064Multi-parametric Imaging in Personalized RadiotherapyCNAO National Center of Oncological Hadrontherapy
- RECRUITINGNCT04832620Image Assisted Optimization of Proton Radiation Therapy in Chordomas and ChondrosarcomasLeiden University Medical Center